A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: against (297), vs. (65)

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulatory Regimen This
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) This regimen will only be available to prescribe at the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

How to switch between AUC CrCl vs EDTA

Description
APPENDIX 3 How to switch between AUC doses calculated using CrCl versus EDTA. If a regimen is defined to calculate Carboplati
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/User-guides/How-to-switch-between-AUC-CrCl-vs-EDTA.docx

Vinorelbine (intravenous)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Intravenous) Regimen NSCLC - Vinorelbine (Intravenous) Indication Secon
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineintravenousver12.pdf

Vinblastine Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA VINBLASTINE Regimen Lymphoma – Vinblastine Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma Toxicity Drug Vinbla
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Vinblastine-Ver-1.1.pdf

Bendamustine-Obinutuzumab

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination with bendamustine f
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

GvHDProphylaxisMethotrexateTDepleted

Description
Chemotherapy Protocol SUPPORT REGIMEN– GvHD PROPHYLAXIS METHOREXATE – T Depleted Allograft GvHD PROPHYLAXIS This regimen will only be available to prescribe at the Wes
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/GvHDProphylaxisMethotrexateTDepleted.pdf

Pentostatin

Description
Chemotherapy Protocol HAIRY CELL LEUKEMIA PENTOSTATIN Regimen • HCL – Pentostatin Indication • Hairy cell leukaemia Toxicity Drug Pentostatin Adverse Ef
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/Pentostatin.pdf

CladribineSC

Description
Chemotherapy Protocol HAIRY CELL LEUKEMIA CLADRIBINE (SC) Regimen • HCL – Cladribine (SC) Indication • Hairy cell leukemia Toxicity Drug Cladribine Adv
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/CladribineSC.pdf

ACCORD-2 master protocol

Description
CONFIDENTIAL ACCORD-2-001 – Master Protocol TITLE PAGE Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-master-protocol.pdf
21 to 30 of 233
Previous 1 2 3 4 5 … Next